Pharmacological properties
Immunological and biological properties
Respibron is an immunomodulator based on a bacterial lysate that increases the body’s resistance to infections due to an increase in the number of serum and secretory antibodies, activation of cellular and humoral factors of non-specific immunity. This leads to a decrease in the frequency and severity of the course of respiratory infections, as well as a reduction in the use of antibiotics.
The technology of mechanical disintegration of microbial cultures makes it possible to isolate native highly immunogenic material from large fragments of the cell walls of microbial cells by removing ballast antigen-inactive and toxic molecules, which allows to induce a high level of production of specific antibodies. Large antigenic structures are well recognized by the immune system, and the structural immutability of the antigenic material, in contrast to widely used methods of chemical lysis of bacteria, allows for the formation of a highly specific response to the most common pathogens of respiratory infections. Respibron has a double mechanism of action:
- activates non-specific resistance (quick protection within 2-4 weeks from the start of taking Respibron) due to membrane antigens that are part of the drug, by activating dendritic cells, neutrophils, macrophages and NK cells; induction of phagocytosis and cell lysis due to stimulation of adhesion of macrophages to bacteria;
- activates specific immunity (long-term protection for several years) by increasing the production level of interleukin (IL-2), specific serum IgA, G, M and sIgA, activation of effector DM4 and DM8 T-lymphocytes, B-lymphocytes.
The immunostimulating properties of Respibron are due to:
- in vitro: by increasing the production of IL-12, IL-2, IL-10 and IFNg (CD4 + Th type 1), the expression of the IL-2 receptor in B-lymphocytes, CD4 + and CD8 + in T-lymphocytes, the number of CD4 + and CD8 + effector T cells;
- in vivo: by increasing the activity of IgM B-lymphocytes of memory (CD24 +, CD27 +), expression of the IL-2 receptor in B-lymphocytes and CD4 + and CD8 + in T-lymphocytes; by increasing the level of secretory IgA on the mucous membranes of the respiratory tract, which ensures inhibition of the attachment of viral and bacterial cells, neutralization of enzymes and toxins of infectious agents, which are especially important in providing Respibron with its prophylactic properties against the agents of acute, chronic and recurrent infections, as well as upper and lower respiratory diseases ways
Respibron is well absorbed in the mucous membrane of the oral cavity, which makes it convenient to use.
Indication
Acute, subacute, recurrent and chronic infections of the upper respiratory tract (SARS, flu, rhinitis, including allergic, sinusitis, laryngitis, tonsillitis, pharyngitis, nasopharyngitis, tonsillitis, epiglottitis); acute, subacute, recurrent or chronic infections and diseases of the lower respiratory tract, including obstructive (tracheitis, tracheobronchitis, bronchitis, bronchiectasis, COPD).Thanks to its immunomodulatory effect, Respibron reduces the number and intensity of cases of acute respiratory diseases in children who are often and for a long time sick, as well as the number of exacerbations of COPD per year and the severity of their course. The drug is used to treat infections resistant to antibiotic therapy, as well as complications of bacterial and viral infections. Respibron is allowed to be used in combination with other drugs (antibiotics and mucolytic agents).
Application
For oral use in adults and children over 2 years of age.
Treatment of acute processes: dissolve 1 tablet under the tongue for 1-2 minutes once a day (it is necessary to refrain from eating for at least 30 minutes). Take daily until symptoms disappear for at least 10 days. The course of treatment involves taking 10 tablets.
Preventive treatment: dissolve 1 tablet under the tongue for 1-2 minutes once a day. The course of treatment is 10 days. After a 20-day break, repeat the 10-day course of taking the drug. The full course of treatment, during which the maximum immunotherapeutic effect is achieved, is 3 months. During the full course of treatment, it is necessary to take 30 tablets of Respibron. That is, Respibron is taken in 3 ten-day courses for 3 months with two 20-day breaks between them.
Younger children are recommended to first crush the tablet, moisten it with boiled water at room temperature and put the resulting mixture in the oral cavity.
Contraindication
Hypersensitivity to the components of the drug.
Side effects
Rarely – occurrence of skin allergic reactions (itching, irritation).
Special instructions
The period of pregnancy and breastfeeding. toxic effects of respibron on animals have not been noted, however, it is recommended to avoid the use of the drug during the first 3 months of confirmed or suspected pregnancy.
The ability to influence the speed of reaction when driving a motor vehicle or working with other mechanisms. The drug does not affect the ability to drive vehicles and work with other mechanisms.
Interactions
Interaction with other drugs, including antibiotics, was not observed.
Overdose
Cases of overdose have not been reported.
Storage conditions
At a temperature not higher than 25 °C.
Reviews
There are no reviews yet.